179 related articles for article (PubMed ID: 11679925)
21. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.
Barnett SW; Rajasekar S; Legg H; Doe B; Fuller DH; Haynes JR; Walker CM; Steimer KS
Vaccine; 1997 Jun; 15(8):869-73. PubMed ID: 9234536
[TBL] [Abstract][Full Text] [Related]
22. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
[TBL] [Abstract][Full Text] [Related]
23. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
Wang X; Uto T; Akagi T; Akashi M; Baba M
J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
[TBL] [Abstract][Full Text] [Related]
24. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
[TBL] [Abstract][Full Text] [Related]
25. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients.
Ackers ML; Parekh B; Evans TG; Berman P; Phillips S; Allen M; McDougal JS
J Infect Dis; 2003 Mar; 187(6):879-86. PubMed ID: 12660933
[TBL] [Abstract][Full Text] [Related]
26. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
[TBL] [Abstract][Full Text] [Related]
27. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein GP120 epitopes correlates with the uninfected status of children born to seropositive mothers.
Dis Markers; 1990; 8(3):159. PubMed ID: 2272149
[No Abstract] [Full Text] [Related]
28. [Experimental study on immune responses induced in mice by gp120 gene vaccine of Chinese HIV-1 strain].
Wang FX; Sun YT; Sun YN; Xu Z; Wang LX; Bai XF; Huang CX
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):282-5. PubMed ID: 15193218
[TBL] [Abstract][Full Text] [Related]
29. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.
Karnasuta C; Paris RM; Cox JH; Nitayaphan S; Pitisuttithum P; Thongcharoen P; Brown AE; Gurunathan S; Tartaglia J; Heyward WL; McNeil JG; Birx DL; de Souza MS;
Vaccine; 2005 Mar; 23(19):2522-9. PubMed ID: 15752839
[TBL] [Abstract][Full Text] [Related]
30. Antibody response to hepatitis B immunization in infants born to HIV-infected mothers.
Thaithumyanon P; Punnahitananda S; Praisuwanna P; Thisyakorn U; Ruxrungtham K
J Med Assoc Thai; 2002 Mar; 85(3):277-82. PubMed ID: 12117014
[TBL] [Abstract][Full Text] [Related]
31. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
[TBL] [Abstract][Full Text] [Related]
32. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
33. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques.
Koopman G; Bogers WM; van Gils M; Koornstra W; Barnett S; Morein B; Lehner T; Heeney JL
J Med Virol; 2007 May; 79(5):474-82. PubMed ID: 17385685
[TBL] [Abstract][Full Text] [Related]
34. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.
Connor RI; Korber BT; Graham BS; Hahn BH; Ho DD; Walker BD; Neumann AU; Vermund SH; Mestecky J; Jackson S; Fenamore E; Cao Y; Gao F; Kalams S; Kunstman KJ; McDonald D; McWilliams N; Trkola A; Moore JP; Wolinsky SM
J Virol; 1998 Feb; 72(2):1552-76. PubMed ID: 9445059
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
[TBL] [Abstract][Full Text] [Related]
36. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
[TBL] [Abstract][Full Text] [Related]
37. In search of a human immunodeficiency virus vaccine.
Bartholomew CF
West Indian Med J; 2000 Sep; 49(3):187-9. PubMed ID: 11076204
[No Abstract] [Full Text] [Related]
38. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
[TBL] [Abstract][Full Text] [Related]
39. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers.
Kahn JO; Sinangil F; Baenziger J; Murcar N; Wynne D; Coleman RL; Steimer KS; Dekker CL; Chernoff D
J Infect Dis; 1994 Nov; 170(5):1288-91. PubMed ID: 7963729
[TBL] [Abstract][Full Text] [Related]
40. AIDS vaccine: efficacy, safety and ethics.
Veljkovic V; Veljkovic N; Glisic S; Ho MW
Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
